Analysed DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) News Sources
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
18-05-2026
yahoo.com
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
07-05-2026
yahoo.com
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
30-06-2026
yahoo.com
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
20-07-2026
yahoo.com
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
17-08-2026
yahoo.com
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
01-09-2026
marketbeat.com
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
14-09-2026
yahoo.com
What is the current price of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)?
The current price of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) is $1.12.
DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) since the previous trading day is $0.
DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)?
The most recent average sentiment score for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)?
The most recent sentiment for DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ) is .
SEC-8K** Filing Available For DOGWOOD THERAPEUTICS INC (DWTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.